Plain-English translation of NCT04989946 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination approach to treat newly diagnosed, high-risk prostate cancer. You would receive , a DNA vaccine designed to train your immune system to recognize and attack prostate cancer cells, combined with one or more immune-boosting medications (like , , or ) and hormone-blocking treatment. All participants would then have prostate surgery to see how well the treatment worked.
Standard hormone-blocking therapy alone has limited success in preventing cancer from coming back in high-risk patients. Researchers believe that adding a vaccine to jumpstart your immune system—along with medications that remove the 'brakes' on immune cells—might help your body fight the cancer more effectively before surgery.
You would be randomly assigned to one of five treatment groups and receive injections of the vaccine starting on day 1, followed by hormone-blocking injections and intravenous infusions of immune-boosting medications on specific dates over about 10 weeks. Throughout this time, you would have regular blood draws and imaging tests to monitor your response. At the end of this period, you would undergo prostate surgery, and your surgical tissue would be examined to see how well the treatment reduced or eliminated cancer cells.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States